INMUNE BIO, INC.

(INMB)
  Report
Delayed Nasdaq  -  04:00 2022-07-06 pm EDT
9.490 USD   +2.26%
06/23INMUNE BIO : USPTO Issues Patent Covering Use of XPro™ for Treatment of CNS Diseases - Form 8-K
PU
06/23INMUNE BIO, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/22INmune Bio Receives US Patent Covering Use of Central Nervous System Diseases Treatment
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

INmune Bio Shares Hit 52-Week Low After FDA Requests More Data on XPro1595

05/24/2022 | 11:46am EDT

By Chris Wack


INmune Bio Inc. shares were down 24% to $5.51 after the company said the Food and Drug Administration requested additional information for chemistry manufacturing and controls of the newly manufactured XPro1595.

The stock hit its 52-week low of $4.63 earlier in the session.

The company said that as part of the communication, the agency placed its investigational new drug application to initiate its phase 2 clinical trial of XPro in patients with Alzheimer's disease in the U.S. on clinical hold.

The FDA indicated it will provide an official clinical hold letter to INmune in about 30 days, the company said.

INmune said it plans to provide additional updates pending discussion with the FDA, and its phase 2 trial of XPro remains open in Australia and continues to enroll patients.

B. Riley Securities cut its ratings for INmune shares to neutral from buy, while cutting its price target to $7 from $14 a share. BTIG cut its price target to $14 from $31 a share, while maintaining its buy rating on the stock.


Write to Chris Wack at chris.wack@wsj.com


(END) Dow Jones Newswires

05-24-22 1346ET

All news about INMUNE BIO, INC.
06/23INMUNE BIO : USPTO Issues Patent Covering Use of XPro™ for Treatment of CNS Diseases..
PU
06/23INMUNE BIO, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/22INmune Bio Receives US Patent Covering Use of Central Nervous System Diseases Treatment
MT
06/22USPTO Issues Patent Covering Use of XPro™ for Treatment of CNS Diseases
GL
06/16INMUNE BIO : Press Release, dated June 16, 2022 - Form 8-K
PU
06/16INMUNE BIO, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/16INmune Bio, Inc. Presents Data on Combination Therapy with INB03™ on Overcoming R..
GL
06/16INmune Bio, Inc. Presents Data on Combination Therapy with INB03™ on Overcoming R..
AQ
06/01INMUNE BIO, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/25INmune Bio Shares Rebound From 52-Week Low, Up 9%
DJ
More news
Analyst Recommendations on INMUNE BIO, INC.
More recommendations
Financials (USD)
Sales 2022 0,12 M - -
Net income 2022 -38,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -4,75x
Yield 2022 -
Capitalization 170 M 170 M -
Capi. / Sales 2022 1 407x
Capi. / Sales 2023 -
Nbr of Employees 10
Free-Float 64,9%
Chart INMUNE BIO, INC.
Duration : Period :
INmune Bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INMUNE BIO, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 9,49 $
Average target price 14,33 $
Spread / Average Target 51,0%
EPS Revisions
Managers and Directors
Raymond J. Tesi Chairman, President, Chief Executive Officer & CMO
David J. Moss Chief Financial Officer, Secretary & Treasurer
Mark Lowdell Director
J. Kelly Ganjei Independent Director
Timothy J. Schroeder Independent Director
Sector and Competitors
1st jan.Capi. (M$)
INMUNE BIO, INC.-6.96%170
GILEAD SCIENCES, INC.-13.61%78 683
VERTEX PHARMACEUTICALS32.59%74 466
REGENERON PHARMACEUTICALS, INC.-5.80%64 098
WUXI APPTEC CO., LTD.-4.67%49 112
BIONTECH SE-37.86%38 932